44 reports of this reaction
3.4% of all HYDROQUINONE reports
#1 most reported adverse reaction
SQUAMOUS CELL CARCINOMA OF SKIN is the #1 most commonly reported adverse reaction for HYDROQUINONE, manufactured by Obagi Cosmeceuticals LLC. There are 44 FDA adverse event reports linking HYDROQUINONE to SQUAMOUS CELL CARCINOMA OF SKIN. This represents approximately 3.4% of all 1,310 adverse event reports for this drug.
Patients taking HYDROQUINONE who experience squamous cell carcinoma of skin should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SQUAMOUS CELL CARCINOMA OF SKIN is moderately reported among HYDROQUINONE users, representing a notable but not dominant share of adverse events.
In addition to squamous cell carcinoma of skin, the following adverse reactions have been reported for HYDROQUINONE:
The following drugs have also been linked to squamous cell carcinoma of skin in FDA adverse event reports:
SQUAMOUS CELL CARCINOMA OF SKIN has been reported as an adverse event in 44 FDA reports for HYDROQUINONE. This does not prove causation, but indicates an association observed in post-market surveillance data.
SQUAMOUS CELL CARCINOMA OF SKIN accounts for approximately 3.4% of all adverse event reports for HYDROQUINONE, making it one of the most commonly reported side effect.
If you experience squamous cell carcinoma of skin while taking HYDROQUINONE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.